200 related articles for article (PubMed ID: 38182756)
21. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Burger JA; Kipps TJ
Blood; 2006 Mar; 107(5):1761-7. PubMed ID: 16269611
[TBL] [Abstract][Full Text] [Related]
22. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
24. P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms.
Lin SY; Dolfi SC; Amiri S; Li J; Budak-Alpdogan T; Lee KC; Derenzo C; Banerjee D; Glod J
Int J Oncol; 2013 Dec; 43(6):1817-23. PubMed ID: 24064862
[TBL] [Abstract][Full Text] [Related]
25. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
26. ROLE OF STROMAL MICROENVIRONMENT IN THE FORMATION OF INVASIVE, ANGIOGENIC, AND METASTATIC POTENTIAL OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Iurchenko NP; Nesina IP; Glushchenko NМ; Buchynska LG
Exp Oncol; 2023 Jun; 45(1):51-61. PubMed ID: 37417282
[TBL] [Abstract][Full Text] [Related]
27. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
28. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
29. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.
Katoh H; Hosono K; Ito Y; Suzuki T; Ogawa Y; Kubo H; Kamata H; Mishima T; Tamaki H; Sakagami H; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Am J Pathol; 2010 Mar; 176(3):1469-83. PubMed ID: 20110411
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
31. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
[TBL] [Abstract][Full Text] [Related]
32. CXCL12 Signaling in the Tumor Microenvironment.
Portella L; Bello AM; Scala S
Adv Exp Med Biol; 2021; 1302():51-70. PubMed ID: 34286441
[TBL] [Abstract][Full Text] [Related]
33. Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer.
Dimitrova P; Vasileva-Slaveva M; Shivarov V; Hasan I; Yordanov A
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109686
[No Abstract] [Full Text] [Related]
34. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.
Givel AM; Kieffer Y; Scholer-Dahirel A; Sirven P; Cardon M; Pelon F; Magagna I; Gentric G; Costa A; Bonneau C; Mieulet V; Vincent-Salomon A; Mechta-Grigoriou F
Nat Commun; 2018 Mar; 9(1):1056. PubMed ID: 29535360
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
37. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
38. The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.
Smit MJ; Schlecht-Louf G; Neves M; van den Bor J; Penela P; Siderius M; Bachelerie F; Mayor F
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():541-563. PubMed ID: 32956018
[TBL] [Abstract][Full Text] [Related]
39. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.
Pelizzo G; Veschi V; Mantelli M; Croce S; Di Benedetto V; D'Angelo P; Maltese A; Catenacci L; Apuzzo T; Scavo E; Moretta A; Todaro M; Stassi G; Avanzini MA; Calcaterra V
BMC Cancer; 2018 Nov; 18(1):1176. PubMed ID: 30482160
[TBL] [Abstract][Full Text] [Related]
40. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
